211 related articles for article (PubMed ID: 33166689)
1. Treatment of Differentiated Thyroid Cancer and Recurrent Laryngeal Nerve Function with 131 Iodine Based on Positron Emission Tomography/Computed Tomography Image Segmentation Algorithm.
Zhong Y; He J; Zhang C; Ardlee B
World Neurosurg; 2021 May; 149():428-435. PubMed ID: 33166689
[TBL] [Abstract][Full Text] [Related]
2. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
Küçük ON; Gültekin SS; Aras G; Ibiş E
Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
[TBL] [Abstract][Full Text] [Related]
4. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
6. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
[TBL] [Abstract][Full Text] [Related]
9. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
[TBL] [Abstract][Full Text] [Related]
10. Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma.
Xu YH; Shen CT; Xue YL; Qiu ZL; Luo QY
Hell J Nucl Med; 2013; 16(3):199-203. PubMed ID: 24251307
[TBL] [Abstract][Full Text] [Related]
11. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
12. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Eur J Nucl Med; 1997 Nov; 24(11):1342-8. PubMed ID: 9371865
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
14. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
15. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
[TBL] [Abstract][Full Text] [Related]
16. 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET).
Kist JW; de Keizer B; van der Vlies M; Brouwers AH; Huysmans DA; van der Zant FM; Hermsen R; Stokkel MP; Hoekstra OS; Vogel WV; ;
J Nucl Med; 2016 May; 57(5):701-7. PubMed ID: 26609180
[TBL] [Abstract][Full Text] [Related]
17. Incremental diagnostic value of [
Dittmann M; Gonzalez Carvalho JM; Rahbar K; Schäfers M; Claesener M; Riemann B; Seifert R
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2639-2646. PubMed ID: 32248325
[TBL] [Abstract][Full Text] [Related]
18. Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic ¹³¹I whole-body scan and detectable serum thyroglobulin levels.
Agate L; Bianchi F; Giorgetti A; Sbragia P; Bottici V; Brozzi F; Santini P; Molinaro E; Vitti P; Elisei R; Ceccarelli C
J Endocrinol Invest; 2014 Oct; 37(10):967-72. PubMed ID: 25070043
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Optimal threshold of stimulated serum thyroglobulin level for
Chai H; Zhang H; Yu YL; Gao YC
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):429-432. PubMed ID: 28585147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
